F

• "Raising awareness about myasthenia gravis is not just about spreading knowledge, it's about empowering those who are living with it.
• Our aim is to enhance patients' quality of life and reduce their mental burden," conclude the founders of the European Myasthenia Gravis Day.
• "The first European Awareness Day for Myasthenia Gravis marks an important milestone towards increasing awareness and understanding of this rare disease.
• Therefore we are very happy that there is finally a European Myasthenia Gravis Day to put a spotlight on this disease."

• The new shot represents six decades of starts and stops in the hunt for a vaccine to curb one of the most common winter respiratory viruses.
• The vaccine, called Arexvy, made by the biopharmaceutical company GSK, is approved for use in adults ages 60 and over.
• The Conversation asked Annette Regan, an epidemiologist and vaccine specialist, to discuss the significance of the first vaccine against RSV and the other RSV vaccine candidates that are in the pipeline.

1. How does the new vaccine protect against the virus?

• The vaccine targets a protein known as RSV F glycoprotein, which is found on the surface of the virus.
• The vaccine also includes an adjuvant, a substance that helps amplify the effect of the vaccine by boosting the immune system’s response.

2. When and for whom will it be available?

• The committee is expected to meet in June 2023 to make a recommendation on the new RSV vaccine, after which the CDC would officially endorse it.
• It could recommend the vaccine for all adults 60 and older, or a subset of older adults.
• Given the lower efficacy for adults ages 80 and older, the committee could place an age cap on the recommendations.

3. Why has the first RSV vaccine been so long in coming?

• One problem that has plagued vaccine manufacturers is the difficulty of identifying an antigen – the piece of the virus that the vaccine targets – that doesn’t change, or shape-shift.
• The F protein of the RSV virus is notorious for changing its shape once it fuses with a host’s cell.
• Early attempts to create an inactivated RSV vaccine in the 1960s were stalled after they caused an enhanced form of RSV disease.

4. What other RSV vaccine candidates are coming down the line?

• The next RSV vaccine under review with the FDA is Pfizer’s RSV vaccine.
• It is similar to the recently approved vaccine except that it has no adjuvant and is bivalent, meaning that it targets both RSV A and RSV B – the two strains of RSV.
• The CDC advisory committee is scheduled to discuss vaccine recommendations in October 2023, making this the likely next possible vaccine available.

• The press release headline originally stated, “Purpose Investments Announces Fund Merger of Purpose Money Market Fund and Purpose High Interest Savings ETF and Name Change of Purpose High Interest Savings ETF.” Purpose would like to clarify that it intends to merge Purpose Money Market Fund into Purpose High Interest Savings ETF on or about January 27, 2023 (the “Effective Date”).
• The current holders of ETF units of the Purpose High Interest Savings ETF will not be affected in any way and will continue to hold ETF units of that fund.
• Additionally, the firm intends to change the name of Purpose High Interest Savings ETF into Purpose High Interest Savings Fund.
• Following the merger, Purpose High Interest Savings ETF will continue to provide an opportunity for preservation of capital and liquidity and monthly distributions.

• ATLANTA, Oct. 24, 2022 /PRNewswire/ -- Rheem , a leading global manufacturer of water heating and HVACR products, announces thelaunch of HotWave , the multipurpose hose sprayer.
• HotWave's plug-and-play design attaches to a garden hose and allows users to heat and access water from a single source.
• With a maximum temperature of up to 115 F, HotWave water temperatures may be adjusted instantly.
• "Rheem is bringing its tankless water heating technology outside the home with HotWave," said David Calkins, product manager at Eemax, a division of Rheem.